[go: up one dir, main page]

WO2006013012A3 - Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) - Google Patents

Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) Download PDF

Info

Publication number
WO2006013012A3
WO2006013012A3 PCT/EP2005/007949 EP2005007949W WO2006013012A3 WO 2006013012 A3 WO2006013012 A3 WO 2006013012A3 EP 2005007949 W EP2005007949 W EP 2005007949W WO 2006013012 A3 WO2006013012 A3 WO 2006013012A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
nap1
napsin
therapeutics
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007949
Other languages
French (fr)
Other versions
WO2006013012A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2006013012A2 publication Critical patent/WO2006013012A2/en
Publication of WO2006013012A3 publication Critical patent/WO2006013012A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human NAP1 which is associated with the cardiovascular diseases, infections, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, respiratory diseases and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, respiratory diseases and inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of NAP1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007949 2004-08-04 2005-07-21 Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) Ceased WO2006013012A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04018443 2004-08-04
EP04018443.4 2004-08-04

Publications (2)

Publication Number Publication Date
WO2006013012A2 WO2006013012A2 (en) 2006-02-09
WO2006013012A3 true WO2006013012A3 (en) 2006-04-06

Family

ID=35427455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007949 Ceased WO2006013012A2 (en) 2004-08-04 2005-07-21 Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)

Country Status (1)

Country Link
WO (1) WO2006013012A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007062411A1 (en) 2007-12-20 2009-06-25 Justus-Liebig-Universität Giessen Medicines for the treatment of fibrosing lung diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO1999060160A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging lung cancer
JP2001172200A (en) * 1999-12-17 2001-06-26 Meneki Seibutsu Kenkyusho:Kk Antibody against human napsin A and pharmaceutical using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO1999060160A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging lung cancer
JP2001172200A (en) * 1999-12-17 2001-06-26 Meneki Seibutsu Kenkyusho:Kk Antibody against human napsin A and pharmaceutical using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRONSHAW REBECCA F ET AL: "Inhibition of human napsin A.", PROTEIN AND PEPTIDE LETTERS, vol. 10, no. 1, February 2003 (2003-02-01), pages 35 - 42, XP009058607, ISSN: 0929-8665 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 23 10 February 2001 (2001-02-10) *
UENO T ET AL: "Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.", BRITISH JOURNAL OF CANCER, vol. 88, no. 8, 22 April 2003 (2003-04-22), pages 1229 - 1233, XP002359371, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
WO2006013012A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010498A3 (en) Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2006013012A3 (en) Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2006010497A3 (en) Diagnostics and therapeutics for diseases associated with choline kinase (chk)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2005101004A8 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1)
WO2006010495A3 (en) Diagnostics and therapeutics for diseases associated with carboxypeptidase a3 (cpa3)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase